65,437 trials
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Mean Percentage Change From Baseline in Spleen Volume at Week 24 — -14.9 Percentage change
Smoking Cessation
Primary: Change in the Skin Conductance Level, Caused by Smoking Cues, Measured Using Script Driven Imagery — 0.107; -0.040 µS — p=0.05
Neoplasms, Breast
Primary: Number of Participants With Intolerable Toxicities in Phase I of the Study — 1 Participants
Refractory Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: CR and Near CR Rates — 39; 22 percentage of participants
Otitis Media
Primary: Number of Subjects With Procedural, Serious and Device-related Adverse Events. — 0 subjects
Contraception
Primary: Use of the IUD for Contraception at Six Months — 49; 51 participants — p=0.24
Psoriasis
Primary: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 — 41.87; 59.17; 9.04 percentage of…
Psoriasis
Primary: Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16 — 46.01; 59.09; 10.88 percentage of…
Carotid Artery Diseases · Atherosclerosis
Primary: Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years — -6.7; 3.4 mm2
Relapsing Multiple Sclerosis
Primary: Annualized Relapse Rate (ARR) at 1 Year — 0.397; 0.288; 0.256 relapses per person-years — p=0.0114
Infant, Small for Gestational Age
Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001
Metastatic Breast Cancer
Primary: Maximum Tolerable Dose (MTD) of Pazopanib — NA mg
Anterior Cruciate Ligament Reconstruction
Primary: Change in International Knee Documentation Committee (IKDC) Subjective Form Score. — 15.5; 12.1 units on a scale
Graft Rejection · Kidney Transplant · Renal Allograft Recipients
Primary: Percentage of Participants With Improvement of Greater Than or Equal to [≥]5 Milliliters Per Minute Per 1.73 Square Meters (mL/Min/m^2) in Calculated Glomerular…
Pertussis · Whooping Cough · Tetanus
Primary: The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine — 30; 33; 32; 35…